OUR MISSION

A LIFETIME OF CLEAR VISION

Visus Therapeutics™ is a clinical-stage company developing innovative medicines to improve vision for people around the world. Our lead program is the pursuit of developing the world’s first presbyopia-correcting eye drop with the potential to last at least eight hours.

OUR GOAL

RESTORING NEAR VISION
TO AGING EYES

By the time most people reach the age of 50, they will develop presbyopia, a progressive condition of the eye that makes it difficult to see at close distances. There are no FDA-approved medicines for presbyopia, and the most common treatments include glasses, contact lenses, or surgery. Visus is dedicated to helping the billions of adults globally who suffer from this condition through the development of its investigational medicine, BRIMOCHOL™ (carbachol + brimonidine tartrate). BRIMOCHOL is being studied as a prescription eye drop designed to correct the loss of near vision associated with presbyopia.

Learn more about our investigational drug pipeline

ABOUT
PRESBYOPIA

Presbyopia is a natural, inevitable part of the aging process and the most common cause of vision impairment. Loss of near vision typically begins when adults reach their mid-40s, and the condition is almost universal by age 50. The vast majority of people will experience presbyopia in their lifetime. It is estimated that presbyopia will affect 2.1 billion people globally in 2020, with approximately 123 million residing in the US.

Learn more about presbyopia

OUR TEAM

INSPIRED BY
THE PROMISE
OF SCIENCE

We are a dedicated team of physicians, scientists, and business leaders that works relentlessly toward our goal of delivering a lifetime of clear vision to the patients we serve.

Learn more about our experienced team

FEATURED NEWS

October 20, 2020
Combination Drop Among Topical Presbyopia Treatments in Development
>
Learn more about our latest developments

Visus Therapeutics, Inc.
500 Yale Avenue N.
Seattle, WA 98109

© VISUS THERAPEUTICS 2020 ALL RIGHTS RESERVED
VISUS THERAPEUTICS and BRIMOCHOL are trademarks of Visus Therapeutics, Inc.